|
See related Inspra film-coated tab information |
|
|
|
Manufacturer |
Pfizer |
|
Distributor |
Hong Kong: Zuellig |
|
Contents |
Eplerenone |
|
Indications |
Reduce the risk of CV mortality & morbidity in stable patients w/ left ventricular dysfunction & clinical evidence of heart failure after recent MI.
Click to view Inspra detailed prescribing infomation |
|
Dosage |
Initially, 25 mg once daily titrated to the target dose of 50 mg once daily preferably w/in 4 wk.
Click to view Inspra detailed prescribing infomation |
|
Overdosage |
View Inspra overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food |
|
Contraindications |
Hyperkalaemia. Patients w/ serum K >5 mmol/L at initiation; moderate to severe renal insufficiency (CrCl <50 mL/min); severe hepatic insufficiency (Child-Pugh class C); those receiving K-sparing diuretics, K supplements or potent CYP3A4 inhibitors eg ketoconazole, itraconazole, ritonavir. HTN. Type 2 diabetes w/ microalbuminuria; serum creatinine >2 mg/dL (males) or >1.8 mg/dL (females).
Click to view Inspra detailed prescribing infomation |
|
Special Precautions |
Monitor serum K & electrolyte levels. Diabetes, microalbuminuria, renal & hepatic impairment. Pregnancy & lactation. Childn. Elderly.
Click to view Inspra detailed prescribing infomation |
|
Adverse Drug Reactions |
Hyperkalaemia, dizziness, hypotension, diarrhoea, nausea, abnormal renal function. Angioneurotic edema, rash.
View ADR Monitoring Form |
|
Drug Interactions |
K-sparing diuretics, NSAIDs, lithium. Mild to moderate CYP3A4 inhibitors eg erythromycin, saquinavir, verapamil, fluconazole; CYP3A4 inducers eg St. John's wort.
View more drug interactions with Inspra |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Mechanism of Action |
View Inspra mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Inspra film-coated tablet |
|
Inspra 25 mg x 30's |
 |
|
Inspra 50 mg x 30's |
 |
|
|
|
Manufacturer: |
Pfizer |
|
Distributor: |
Hong Kong: Zuellig |
|
|
|
